| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Adrenocorticotropic hormone (ACTH) (1-39), in humans (ACTH 1-39), a member of the melanocortin family, increases the production of CS initially but also in the central nervous system (CNS) and immune cells. ACTH 1-39 externally protects neuronal platforms from numerous cellular, excitotoxic and hazard-related damage [1]. Conditioned medium (CM) was generated from untreated astrocyte (AS) cultures and AS cultures treated with 200 nM ACTH 1-39 for 24 h, washed to remove ACTH 1-39, and then in DMEM Dye for another 24 hours. In initial investigations, oligodendrocyte (OL) viability was not found in the presence of OL-formulated medium with 2% newborn calf serum (NCS) or AS CM (made in DMEM with clear serum). difference. Similar results on OL viability were found after 24 hours in most cases of OL introduction at 1% to 4% MG (MG) CM. In subsequent experiments, the control in each experiment consisted of OL in specified cells containing 2% NCS [2] .
|
|---|---|
| References |
[1]. Lisak RP, et al. Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage. Exp Neurol. 2015 Nov;273:161-7.
[2]. Lisak RP, et al. The melanocortin ACTH 1-39 promotes protection of oligodendrocytes by astroglia. J Neurol Sci. 2016 Mar 15;362:21-6 |
| Molecular Formula |
C207H308N56O58S
|
|---|---|
| Molecular Weight |
4541.07
|
| CAS # |
12279-41-3
|
| Related CAS # |
Adrenocorticotropic Hormone (ACTH) (1-39), human(TFA);Adrenocorticotropic Hormone (ACTH) (1-39), human acetate
|
| SMILES |
N1(CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1C=CC=CC=1)C(O)=O)CC(N)=O)C(=O)[C@H](CC1C=CC(=CC=1)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(CNC(=O)[C@H](CC1C2C=CC=CC=2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C=CC(=CC=1)O)NC(=O)[C@H](CO)N)=O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL (~11.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (22.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2202 mL | 1.1011 mL | 2.2021 mL | |
| 5 mM | 0.0440 mL | 0.2202 mL | 0.4404 mL | |
| 10 mM | 0.0220 mL | 0.1101 mL | 0.2202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
